Kiland Julie A

Torné Odalys, Oikawa Kazuya, Teixeira Leandro B C, Kiland Julie A, McLellan Gillian J

This study found that a feline congenital glaucoma model with an LTBP2 mutation shows early trabecular meshwork abnormalities (disorganized elastic fibers, altered cell shape, collapsed spaces) by 2-5 weeks, preceding significant eye pressure elevation.

Oikawa Kazuya, Kiland Julie A, Mathu Virginia, Torne Odalys, Wickland Colton, Neufcourt Sarah et al.

Telmisartan did not lower IOP or improve ocular perfusion in glaucomatous cats, but it was well-tolerated without detrimental effects on blood pressure, suggesting it's not a sole glaucoma therapy.

Oikawa Kazuya, Torne Odalys, Sun David, Moon Alaina K B, Kiland Julie A, Trane Ralph Møller et al.

This feline glaucoma study found elevated aqueous humor TGF-β2, locally produced in the eye, strongly correlates with high IOP, suggesting it's a therapeutic target.

Chan Kore, Hoon Mrinalini, Pattnaik Bikash R, Ver Hoeve James N, Wahlgren Brad, Gloe Shawna et al.

Vigabatrin treatment in mice caused retinal GABA increases, altered ERG signals, and neuron remodeling, despite no thinning, suggesting retinal toxicity mechanisms like high VGB concentration and plasticity contribute to visual field loss.

Heyne Galen W, Kiland Julie A, Kaufman Paul L, Gabelt B'Ann T

Topical nitric oxide donor (SNP) significantly lowered monkey IOP by increasing outflow facility, suggesting NO-enhancing therapies could be useful for glaucoma.